
|Articles|December 16, 2016
ImmunoCellular Therapeutics Names New CEO
December 16, 2016
Advertisement
ImmunoCellular Therapeutics (Los Angeles, CA) announced that its Board of Directors has appointed Anthony Gringeri, Ph.D, as Chief Executive Officer. The appointment follows the decision by Andrew Gengos to resign the position of CEO. Mr. Gengos will continue to play an active role with the company as a member of the Board of Directors, the company reports. Dr. Gringeri has served as ImmunoCellular's Senior Vice President of Strategic Resources since August 2013. He joined ImmunoCellular from ViaCyte, where he was Vice President and Chief Development Officer. He previously served as Chief Operating Officer for Amsterdam Molecular Therapeutics.
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
Artisan Partners’ Director Calls for Novartis Board Shake-Up
2
The Agentic AI Revolution in Biopharma
3
340B Under Pressure: Inside Pharma's Push for Greater Clarity
4
Kura Oncology Spins Out Caspian Therapeutics With $50 Million to Test Menin Inhibition as a Disease-Modifying Approach to Diabetes
5




